Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes
Status:
Recruiting
Trial end date:
2022-08-08
Target enrollment:
Participant gender:
Summary
This phase 1 study will include patients suffering from type 2 diabetes mellitus and will
study their response to enteric coated aspirin at a dose of 80 mg per day for a 7-day period.
The aims are to determine the feasibility of a phase 2 larger scale trial, and to
characterize the prevalence of incomplete platelet inhibition after exposure to EC aspirin at
doses of 80 mg once daily. Platelet function will be assessed at baseline and a day 7.